Skip to main content
. 2017 Oct 17;7(19):4753–4762. doi: 10.7150/thno.21687

Figure 4.

Figure 4

Dynamic changes in TP53 mutational burden in cfDNA could predict the objective response. Patients with PR experienced a significant reduction in TP53 mutational burden, while patients with SD or PD experienced increased TP53 mutational burden after several cycles of chemotherapy (different colors stand for different patients).